Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis

Can J Gastroenterol. 2004 Jun;18(6):397-9. doi: 10.1155/2004/360537.

Abstract

Inclusion body myositis (IBM) is a progressive degenerative skeletal muscle disease leading to weakening and atrophy of both proximal and distal muscles. Dysphagia is reported in up to 86% of IBM patients. Surgical cricopharyngeal myotomy may be effective for cricopharyngeal dysphagia and there is one published report that botulinum toxin A, injected into the cricopharyngeus muscle using a hypopharyngoscope under general anesthesia, relieved IBM-associated dysphagia. This report presents the first documentation of botulinum toxin A injection into the upper esophageal sphincter using a flexible esophagogastroduodenoscope under conscious sedation, to reduce upper esophageal sphincter pressure and successfully alleviate oropharyngeal dysphagia in two IBM patients.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Botulinum Toxins, Type A / administration & dosage
  • Botulinum Toxins, Type A / therapeutic use*
  • Conscious Sedation
  • Deglutition Disorders / etiology
  • Deglutition Disorders / therapy*
  • Endoscopes, Gastrointestinal
  • Esophagogastric Junction / physiopathology*
  • Humans
  • Injections, Intramuscular
  • Male
  • Middle Aged
  • Myositis, Inclusion Body / complications*
  • Neuromuscular Agents / administration & dosage
  • Neuromuscular Agents / therapeutic use*
  • Oropharynx / physiopathology*
  • Pressure

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A